Postoperative Adjuvant Chemotherapy for Thymic Cancer (FUSCC-Thymic 3)

Inclusion Criteria: 1. Voluntarily participate and sign an informed consent form in writing; 2. Age range from 18 to 75 years old, regardless of gender; 3. Within 3 months after the surgery is completed; 4. Histologically diagnosed with thymic cancer; 5. Complete resection based on surgical records, pathological reports, and postoperative imaging; 6. Masaoka stage: I-III 7. No severe hematopoietic function, heart, lung, liver, kidney dysfunction, or immune deficiency; 8. White blood cells ≥ 3 × 109/L; Neutrophils ≥ 1.5 × 109/L; Hemoglobin ≥ 10 g/dL; Platelets ≥ 100 × 109/L; Total bilirubin ≤ 1.5 times the upper limit of normal value; AST (SGOT)/ALT (SGPT) ≤ 2.5 times the upper limit of normal value; Creatinine ≤ 1.5 times the upper limit of normal value; Exclusion Criteria: 1. Having a second primary tumor (excluding cured non malignant melanoma of the skin, papillary thyroid carcinoma, stage I seminomatoma, cervical carcinoma in situ, or other curable tumors that have been tumor free for more than 3 years after treatment); 2. Symptomatic coronary heart disease, left heart failure, uncontrollable seizures, or loss of self-awareness due to mental illness; 3. Pregnancy and lactation period; 4. Patients with drug addiction, chronic alcoholism and AIDS; 5. Researchers believe that participants are not suitable for this experiment.